Study guide

8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid

Key Takeaways Explain This Topic AI

Fertilization occurs in the ampulla, implantation begins about 6–7 days after fertilization, and the syncytiotrophoblast produces hCG detectable in maternal serum about 8–11 days after conception.

Organogenesis spans post-conception weeks 3–8 (about 5–10 weeks from the LMP), the period of greatest structural teratogen risk.

The placenta takes over progesterone production from the corpus luteum at about 7–10 weeks and actively transfers maternal IgG, most in the third trimester.

Fetal circulation uses three shunts (ductus venosus, foramen ovale, and ductus arteriosus); NSAIDs in late pregnancy can constrict the ductus arteriosus prematurely.

After about 16–20 weeks, amniotic fluid comes mainly from fetal urine and is removed by fetal swallowing, so renal agenesis causes oligohydramnios and esophageal atresia causes polyhydramnios.

Last updated: October 2026

From Fertilization to Implantation

Fertilization occurs in the ampulla of the fallopian tube, usually within 12–24 hours of ovulation; sperm can survive up to about 5 days in fertile cervical mucus.

The zygote divides into a morula (about day 3) and then a blastocyst (about day 5) with an inner cell mass (the embryo) and an outer trophoblast (the placenta).

Implantation begins about day 6–7 after fertilization and is complete by about day 10. The trophoblast differentiates into the invasive syncytiotrophoblast , which secretes hCG , and the cytotrophoblast .

hCG maintains the corpus luteum and is detectable in maternal serum about 8–11 days after fertilization, roughly when the next period is due.

Developmental Periods and Milestones

Embryologists count from conception; clinicians count gestational age from the LMP, about 2 weeks earlier.

  • Period Post-Conception Timing Gestational Age (from LMP) Key Events
  • Pre-embryonic ("all-or-none") Weeks 1–2 Weeks 3–4 Teratogens either cause loss or have no effect

Embryonic (organogenesis) Weeks 3–8 Weeks 5–10 Neural tube closes by day 28 after conception; heart beats by about 6 weeks GA; limbs, face, and palate form; greatest structural teratogen risk

Fetal Week 9 to birth Week 11 to term Growth and functional maturation; teratogens cause growth restriction or functional deficits

Other milestones (gestational age): Fetal thyroid begins functioning at about 10–12 weeks (before then the embryo depends on maternal thyroxine). External genitalia become distinguishable on ultrasound by about 12–14 weeks. Quickening is felt at 16–20 weeks. Surfactant production begins at about 24 weeks and is usually adequate by 34–36 weeks. Periviability is about 22–25 weeks.

The Placenta

At term the placenta weighs about 500 g. Maternal blood enters the intervillous space from spiral arteries, which trophoblast remodels into low-resistance vessels; failure of this remodeling underlies preeclampsia and fetal growth restriction.

Transfer Mechanisms

  • Substance Mechanism
  • Oxygen, CO2, and small lipophilic drugs Simple diffusion
  • Glucose Facilitated diffusion (GLUT1), so maternal hyperglycemia passes to the fetus
  • Amino acids, calcium, iron Active transport

IgG antibodies Receptor-mediated transport (FcRn), mostly in the third trimester ; this is how Tdap, influenza, COVID-19, and RSV vaccines protect newborns, and how maternal anti-D, anti-Ro, and thyroid antibodies reach the fetus

Insulin, heparin, and large molecules Generally do not cross; this is why insulin and low-molecular-weight heparin are preferred in pregnancy

Placental Hormones

hCG: Peaks at 8–10 weeks; sustains the corpus luteum and stimulates the TSH receptor (which can cause transient gestational hyperthyroxinemia).

Human placental lactogen: Rises through pregnancy and creates the insulin resistance behind gestational diabetes.

Progesterone: From the corpus luteum until the luteal-placental shift at about 7–10 weeks , then from the placenta; maintains uterine quiescence.

Estriol: Made by the placenta from fetal adrenal DHEA-S converted in the fetal liver, so it reflects fetal and placental health (a quad-screen marker).

The Umbilical Cord

The cord normally contains two arteries (carrying deoxygenated blood from the fetus to the placenta) and one vein (carrying oxygenated blood to the fetus), cushioned by Wharton's jelly. A single umbilical artery (about 0.5%–1% of births) is linked to fetal anomalies and growth restriction, so it warrants a detailed anatomy scan and growth surveillance. In a velamentous insertion , vessels run unprotected through the membranes, raising the risk of vasa previa.

Fetal Circulation

Oxygenated blood travels from the placenta through the umbilical vein .

About half bypasses the liver through the ductus venosus into the inferior vena cava.

In the right atrium, most of this oxygen-rich blood crosses the foramen ovale to the left atrium and left ventricle, supplying the brain and coronary arteries.

Blood from the superior vena cava goes to the right ventricle and pulmonary artery, where most bypasses the high-resistance lungs through the ductus arteriosus into the descending aorta.

Fetal hemoglobin has a higher oxygen affinity than adult hemoglobin, which helps the fetus extract oxygen.

At birth, lung expansion drops pulmonary vascular resistance, left atrial pressure rises and closes the foramen ovale, and rising oxygen and falling prostaglandins close the ductus arteriosus within days. Clinically, NSAIDs such as indomethacin can constrict the ductus arteriosus prematurely when used after about 30–32 weeks, which is why their use in pregnancy is time-limited.

Amniotic Fluid

Early fluid is a transudate of maternal plasma; after about 16–20 weeks, fetal urine is the main source, and fetal swallowing and lung secretions handle turnover.

Volume peaks at about 800–1,000 mL around 34–36 weeks, then declines.

Oligohydramnios (deepest vertical pocket <2 cm or AFI ≤5 cm): renal agenesis or obstruction, PPROM, placental insufficiency, or post-term pregnancy; prolonged early oligohydramnios causes pulmonary hypoplasia and limb contractures.

Polyhydramnios (deepest pocket ≥8 cm or AFI ≥24 cm): maternal diabetes, impaired fetal swallowing (esophageal or duodenal atresia, anencephaly), fetal anemia, or idiopathic causes.

Twinning and Chorionicity

Dizygotic twins (two eggs) are always dichorionic-diamniotic . In monozygotic twins, chorionicity depends on when the embryo divides:

  • Timing of Division After Fertilization Placentation
  • Days 0–3 Dichorionic-diamniotic
  • Days 4–8 Monochorionic-diamniotic (risk of twin-twin transfusion syndrome)
  • Days 8–12 Monochorionic-monoamniotic (cord entanglement)
  • After about day 13 Conjoined twins

First-trimester ultrasound is the best time to determine chorionicity (lambda sign for dichorionic; T sign for monochorionic), and chorionicity sets the surveillance plan.